Teleflex Incorporated $TFX Shares Sold by Amundi

Key Points

• Amundi cut its Teleflex stake by 70.7% in the second quarter, selling 27,312 shares and retaining 11,294 shares valued at approximately $1.43 million. Institutional investors collectively own 95.62% of the company.
• Analyst sentiment is mixed but leans positive, with a consensus “Hold” rating and a $152.90 price target. Recent targets range from $145 to $170, including upgraded “Buy” and “Outperform” recommendations.
• Teleflex exceeded quarterly earnings and revenue expectations, reporting adjusted EPS of $1.76 and revenue of $570.33 million, up 28.9% year over year. The company also declared a quarterly dividend of $0.34 per share, equivalent to a 1.0% annual yield.

Amundi lowered its position in Teleflex Incorporated (NYSE:TFX - Free Report) by 70.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,294 shares of the medical technology company's stock after selling 27,312 shares during the quarter. Amundi's holdings in Teleflex were worth $1,432,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. California State Teachers Retirement System grew its stake in shares of Teleflex by 12,426.5% in the second quarter. California State Teachers Retirement System now owns 6,447,647 shares of the medical technology company's stock worth $817,304,000 after purchasing an additional 6,396,175 shares in the last quarter. BlackRock Inc. bought a new stake in shares of Teleflex during the second quarter valued at about $688,537,000. Jupiter Topco LLC acquired a new stake in Teleflex in the second quarter worth about $550,456,000. Janus Henderson Group PLC lifted its holdings in Teleflex by 1.1% in the first quarter. Janus Henderson Group PLC now owns 4,291,311 shares of the medical technology company's stock worth $513,281,000 after purchasing an additional 45,199 shares during the period. Finally, AQR Capital Management LLC grew its position in Teleflex by 478.1% in the 3rd quarter. AQR Capital Management LLC now owns 2,366,131 shares of the medical technology company's stock valued at $287,603,000 after buying an additional 1,956,811 shares in the last quarter. Institutional investors own 95.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on TFX. Mizuho increased their price objective on shares of Teleflex from $140.00 to $145.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Piper Sandler reissued an "overweight" rating and set a $169.00 target price (up from $160.00) on shares of Teleflex in a report on Friday, August 7th. Wall Street Zen upgraded Teleflex from a "sell" rating to a "hold" rating in a research report on Sunday, August 9th. Needham & Company LLC increased their price target on Teleflex from $159.00 to $170.00 and gave the company a "buy" rating in a research note on Tuesday, August 25th. Finally, BMO Capital Markets assumed coverage on Teleflex in a research report on Wednesday, July 8th. They set an "outperform" rating and a $159.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $152.90.

Teleflex Price Performance

TFX stock opened at $130.85 on Monday. Teleflex Incorporated has a one year low of $100.18 and a one year high of $145.00. The firm has a 50-day moving average of $135.72 and a two-hundred day moving average of $128.10. The firm has a market capitalization of $5.54 billion, a PE ratio of -5.62, a P/E/G ratio of 0.87 and a beta of 0.82. The company has a current ratio of 2.60, a quick ratio of 2.12 and a debt-to-equity ratio of 0.94.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical technology company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.28 by $0.48. Teleflex had a negative net margin of 39.67% and a positive return on equity of 11.93%. The business had revenue of $570.33 million during the quarter, compared to the consensus estimate of $559.59 million. During the same quarter in the prior year, the firm earned $3.73 EPS. The firm's quarterly revenue was up 28.9% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.900-7.200 EPS. On average, analysts forecast that Teleflex Incorporated will post 7.26 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Friday, August 14th will be issued a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Friday, August 14th. Teleflex's dividend payout ratio (DPR) is currently -5.84%.

About Teleflex

Teleflex Incorporated is a global medical technology company that develops, manufactures and supplies specialty medical devices for hospitals, clinicians and other health care providers. Its products are designed to support procedures in areas including vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgery and urology.

The company's portfolio includes Arrow branded vascular access and catheter products, airway management devices, regional anesthesia products, surgical instruments, interventional devices and urological products.

Want to see what other hedge funds are holding TFX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teleflex Incorporated (NYSE:TFX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.